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Abstract
Aims/hypothesis The hyperinsulinaemic–hypoglycaemic glucose clamp technique has been developed and applied to assess
effects of and responses to hypoglycaemia under standardised conditions. However, the degree to which the methodology of
clamp studies is standardised is unclear. This systematic review examines how hyperinsulinaemic–hypoglycaemic clamps have
been performed and elucidates potential important differences.
Methods A literature search in PubMed and EMBASE was conducted. Articles in English published between 1980 and 2018,
involving adults with or without diabetes, were included.
Results A total of 383 articles were included. There was considerable variation in essential methodology of the hypoglycaemic
clamp procedures, including the insulin dose used (49-fold difference between the lowest and the highest rate), the number of
hypoglycaemic steps (range 1−6), the hypoglycaemic nadirs (range 2.0–4.3 mmol/l) and the duration (ranging from 5 to
660 min). Twenty-seven per cent of the articles reported whole blood glucose levels, most venous levels. In 70.8% of the studies,
a dorsal hand vein was used for blood sampling, with some form of hand warming to arterialise venous blood in 78.8% of these.
Key information was missing in 61.9% of the articles.
Conclusions/interpretation Although the hyperinsulinaemic–hypoglycaemic clamp procedure is considered the gold standard to
study experimental hypoglycaemia, a uniform standard with key elements on how to perform these experiments is lacking.
Methodological differences should be considered when comparing results between hypoglycaemic clamp studies.
PROSPERO registration This systematic review is registered in PROSPERO (CRD42019120083).
Keywords Diabetes . Diabetes mellitus . Human . Hyperinsulinaemic–hypoglycaemic clamp . Hypoglycaemia . Systematic
review . Type 1 diabetes . Type 2 diabetes
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BSA Body surface area
CGM Continuous glucose monitoring
GIR Glucose infusion rate
IHSG International Hypoglycaemia Study Group
IIR Insulin infusion rate
PRISMA Preferred Reporting Items for Systematic
Reviews and Meta-Analyses
Introduction
Despite important advances in the manufacturing of insulin
agents, insulin administration and glucose monitoring,
hypoglycaemia remains the most frequent adverse event in
people with diabetes treated with insulin and is associated
with increased morbidity and mortality [1]. Revealing the still
many knowledge gaps in understanding the pathophysiology
of, responses to and effects of hypoglycaemia is therefore
important.
In the 1970s, the hyperinsulinaemic–normoglycaemic
clamp technique was developed for quantification of beta cell
sensitivity to glucose and of tissue sensitivity to insulin [2, 3].
The hyperinsulinaemic–hypoglycaemic clamp technique is a
variant of this method, designed to assess clinical manifesta-
tions of hypoglycaemia, including counterregulatory hormone
responses, symptomatic awareness and cognitive function,
under standardised conditions [4, 5]. It consists of continuous
intravenous insulin infusion at a (relatively) high dose to
ensure sufficient glucose lowering and a variable infusion of
glucose guided by glucose measurements performed at regular
time intervals to achieve stable glucose values at pre-defined
target(s). Two forms can be distinguished, involving either a
single glucose target (single-step clamp) or multiple decre-
mental targets in the hypoglycaemic range (stepped clamp).
A universally accepted standardised protocol for the
hyperinsulinaemic–hypoglycaemic clamp would allow for
meta-analysis with increased statistical power when different
studies are compared. However, to the best of our knowledge,
no previous article has been published that sets out standards for
performing hypoglycaemic clamp experiments, for instance
with respect to the optimal glucose target or duration of the
clamp. Differences in its executionmay affect the validity when
data from clamp studies are compared or render it impossible to
compare study results. In this review, we provide a comprehen-
sive overview on how hyperinsulinaemic–hypoglycaemic
clamps have been performed in humans and elucidate differ-
ences and similarities in their execution.
Methods
We performed a descriptive systematic review in accordance
with the published protocol in PROSPERO (https://www.crd.
york.ac.uk/prospero/display_record.php?RecordID=120083).
All peer-reviewed articles available online reporting
Diabetologia
hyperinsulinaemic–hypoglycaemic clamps involving adults
with type 1 diabetes or type 2 diabetes or without diabetes
(healthy participants) were included. Only English language
articles were included in this review. All articles from studies
in which participants had undergone a hyperinsulinaemic–
hypoglycaemic clamp were read. If multiple articles were
published from the same study, only the first published article
with a sufficient clamp description was included, and the
hyperinsulinaemic–hypoglycaemic clamp needed to be the
main method of the study. Studies involving animals or with
inadequate descriptions on how the clamp was performed
were excluded. Reporting is in accordance with the
Preferred Reporting Items for Systematic Reviews and
Meta-Analyses (PRISMA) guidelines [6].
Data sources and search strategy
A literature search was conducted in PubMed and EMBASE
in November 2018. All articles available online in the data-
bases were included, resulting in the inclusion of articles from
1980 to 2018. The search used a combination of free text
words and MeSH (PubMed) and Emtree (EMBASE) terms.
All titles and abstracts identified from the electronic search via
PubMed and EMBASE were imported to COVIDENCE soft-
ware, version 1.0 (https://www.covidence.org/), accessed in
November 2018, a program that streamlines the review
process. The search strategy was developed in collaboration
with an information specialist at Nordsjællands Hospital with
input from clinicians and academics in the review team. The
search strategy for PubMed is available in the supplementary
material (electronic supplementary material [ESM] Methods).
Study selection
Duplicates from the two searches were automatically removed
when imported into COVIDENCE, version 1.0 (https://www.
covidence.org/), accessed in November 2018. All titles and
abstracts were assessed independently to identify articles
requiring full-text review against the inclusion and exclusion
criteria. This first step was done by one reviewer (T.W.
Fabricius), using the words ‘clamp’ and ‘hypoglycaemia’.
Eligible articles identified after title and abstract review
underwent all full-text reading, and the reference lists were
searched for other articles. This step was carried out by two
reviewers (T.W. Fabricius and C.E.M. Verhulst). For this
review we focused on type 1 diabetes, type 2 diabetes and
people without diabetes; studies in children were included.
Studies exclusively performed in patients with other condi-
tions were excluded (ESM Methods). An extraction sheet
was used to extract the desired information from each article.
Any disagreements between the reviewers were resolved by
consensus and in consultation with one of the senior authors
(U. Pedersen-Bjergaard and B.E. de Galan). The list of the
included articles is shown in the supplementary material
(ESM Methods, ESM Table 1).
Data extraction
We extracted information from the articles with our main
focus on the procedure and the quality of the clamp, including
duration of the clamp, number of glucose steps, glucose levels
targeted and achieved, duration of target glucose levels, type
of insulin and insulin infusion rates (IIRs) used, source of
blood sampling (venous, arterial, capillary; arterialisation
method in the case of venous blood) and type of glucose
analyser used. Furthermore, we collected study characteristics
such as author identification, year of publication, type of study
and characteristics of the study population.
Statistics
Results are shown with descriptive statistical methods. We
report the continuous data as means with standard deviations
in the case of normal distribution, and as medians with inter-
quartile ranges when data are not normally distributed.
Statistical analyses were performed using IBM SPSS
Statistics version 25. A p value <0.05 was considered statisti-
cally significant.
Results
A total of 3885 articles were found on PubMed and EMBASE
(Fig. 1). After the process of screening, 408 articles fulfilled
the inclusion criteria, after which 25 articles were excluded
because of inadequate clamp description. A total of 383 arti-
cles were thus included for analysis. In total, 38.1% of the 383
articles (146 articles) contained all information on the clamp
procedures for which we searched.
Participants
The 383 articles analysed included a total of 6993 participants.
The median number of participants in the studies was 15
(IQR: 10–22).Most of the participants examined in the studies
were healthy individuals, followed by participants with type 1
diabetes, with only a few studies enrolling people with type 2
diabetes. There was a preponderance of male participants in
the studies and the participants were relatively young
(Table 1).
Instructions and preparation
Most of the hyperinsulinaemic–hypoglycaemic clamps were
scheduled in the morning. In 80.9% of all studies, participants
were instructed to fast overnight prior to the clamp day. In
Diabetologia
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Fig. 1 PRISMA flow diagram
Table 1 Baseline characteristics
of participants Characteristic Type 1 diabetes Type 2 diabetes No diabetes
No. articles (%) 174 (45.4) 30 (7.8) 268 (70.0)
No. participants (%) 2768 (39.6) 485 (6.9) 3740 (53.5)
Age, years 31.6 ± 7.8 55.1 ± 8.4 30.7 ± 12.6
Male sex, % 62.8 67.6 65.0
HbA1c
mmol/mol 65 ± 16 60 ± 13 34 ± 4
% 8.1 ± 1.4 7.7 ± 1.2 5.3 ± 0.3
Diabetes duration, years 14.3 ± 6.0 9.3 ± 5.4
BMI, kg/m2 24.4 ± 1.9 29.6 ± 2.6 24.0 ± 2.2
Type 2 diabetes glucose-lowering treatment (%)
Diet 7 (23.3)
Oral agents alone 28 (93.3)
Insulin 15 (50)
Not provided 1 (3.3)
Data are shown as n (%) or mean (± SD)
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21.4% of the articles there were other dietary restrictions such
as a weight-maintaining diet 3 days before the clamp (n = 40,
10.4%), a standardised meal the evening before the clamp
(n =12, 3.1%) or a standard breakfast on the morning of the
clamp (n = 8, 2.1%) (ESM Table 2). Participants were also
instructed to abstain from drinking alcohol (13.6%), smoking
tobacco (4.7%), engaging in exercise (11.5%) and ingesting
caffeine (8.6%). In 23.0% of the experiments involving people
with diabetes, an overnight low-dose insulin infusion was
provided to normalise glucose levels prior to the clamp. In
3.9% of the experiments, participants were instructed to
measure or monitor blood glucose overnight by finger stick
or continuous glucose monitoring (CGM) to ensure avoidance
of nocturnal hypoglycaemia, which necessitated rescheduling
of the clamp.
Clamp procedure
Human soluble insulin was used in 65.5% of the clamps, a
rapid-acting analogue insulin in 1.6% and both types of insu-
lin in 0.5%, whereas 32.4% of the articles did not report the
type of insulin used (about 42.6% of which were published
before market introduction of insulin analogues). Glucose (or
dextrose) was administered as a 20% solution in 74.7% of the
studies and as another solution in 6.5%, whereas 18.8% of the
articles did not provide the glucose percentage used.
Two methods were used to calculate the IIR, i.e. based on
body weight (mU or pmol kg−1 min−1) in 257 articles (67.1%)
or on body surface area (BSA) (mU or pmol m−2 min−1) in 110
articles (28.7%). Sixteen articles (4.2%) did not report how the
IIR was calculated. There was considerable variation in IIR
across studies, ranging from 0.25 to 12.0 mU kg−1 min−1 for
studies calculating IIR by body weight and from 15 to
160 mU m−2 min−1 for studies using body surface area (Fig.
2). When recalculating IIR to a person of average body weight
and height (75 kg, 180 cm), mean ± SD IRR corresponded to
7.1 ± 4.1 U/h (range 1.1–54.0 U/h) based on body weight and
7.7 ± 2.6 U/h (range 1.75–18.6 U/h) based on BSA, respective-
ly. There were no significant differences in the IIR between the
single-step and stepped clamps, although in 38 (9.9%) of the
latter the IIR was increased to reach the deepest hypoglycaemic
level. Information about the glucose infusion rate (GIR) was
provided by 24.8% of the studies.
Of the studies reporting plasma insulin levels during the
clamp (n = 147, 38.4%), the mean CVs of these levels for
IIR based on body weight and BSA were 28 ± 16 vs 32 ±
35% (p = 0.70), respectively.
In 89.0% of the clamps, venous blood was sampled for
glucose and other measurements, whereas arterial blood was
sampled in 2.3%. Four articles reported both venous and arterial
blood sampling and 7.6% of the studies did not specify the source
of blood sampling. Glucose was measured in plasma in 271 arti-
cles (70.8%) and in whole blood in 105 (27.4%), with 7 articles
(1.8%) not providing this information. Because of the different
methods of glucose measurement, we converted whole blood
glucose values to plasma glucose values, assuming plasma
glucose levels to be 11.1% higher compared with whole blood
measurements [7]. The most widely reported location of the
venous catheter for blood sampling was in a dorsal hand vein
(70.9%), followed by veins in the antecubital region (6.8%), the
forearm (6.2%) and the leg (0.8%). In 15.3% of the articles, the
location of the catheter was not provided.
A method for arterialisation of venous blood was reported by
272 (78.8%) of the studies using venous cannulations. The
methods used to arterialise venous blood varied, but the applica-
tion of a heated hand box method was used most often (66.4%),
followed by the use of a blanket (4.6%), a pad (1.7%), other
means (1.7%) or an unspecified method (4.3%). In 21.2% of
the articles, hand warming was not applied. Of all the 229 studies
that used a heated box, its temperature was set at 50–60°C in
48.5%, at 60–70°C in 30.1% or at 60°C in 15.7% of the experi-
ments.A temperature below50°Cwas used in 1.3%of the articles
and 4.4%did not provide the target temperature of the heated box.
In two studies, arterialisation of venous blood was checked by
blood gas analyses.
Glucose levels were measured at 5 min intervals in 82.5% of
the studies. Shorter time intervals (down to 1.5 min) were used in
10.0% and longer intervals up to 30 min in 7.5% of the studies.
Glucose levels were mostly determined with the Beckman
Glucose Analyzer (39.2%) or the Yellow Spring Instruments
Glucose Analyzer (36.0%). At regular intervals, bloodwas drawn
to determine counterregulatory hormones, i.e. glucagon, catechol-
amines, growth hormone and cortisol, in 86.2% of the studies.
From 222 articles (58.0%), it was possible to extract
(n =18) or calculate (n =204) the CV of glucose levels











































Fig. 2 Individual IIRs are shown in a box, representing 25th–75th
percentiles, and whiskers showing 10th and 90th percentiles, and are
expressed in units per hour (U/h), mU kg−1 min−1 and mU m−2 min−1,
normalised for a ‘standard person’ with a weight of 75 kg and a height of
180 cm
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calculated, the CV of the normoglycaemic and hypoglycaemic
phases averaged 7 ± 6% and 10 ± 9%, respectively
(p < 0.0005). The overall mean CV of the normo- and
hypoglycaemic phases combined in these clamps was 8.3 ±
7%, with 72 clamps (32.4%) having a mean CV <5%, 91
(41%) a mean CV of 5–10%, 51 (23.0%) a mean CV of 11–
20% and eight a mean CV of more than 20%. Of the 18
articles reporting the calculated CV, all had a CV <10%.
Type of clamp
A single-step hypoglycaemic clamp was performed in 245
(64.0%) of the articles and a stepped clamp in 135 (35.2%),
whereas three (0.8%) articles applied both single-step and
stepped clamps on separate days.
Single-step clamp In 192 of the 248 articles (77.4%) using
single-step clamps, a normoglycaemic phase preceded the
hypoglycaemic phase, the duration of which ranged from 15
to 330 min, with 30 min (23.0%), 60 min (17.7%) or 120 min
(12.9%) most often used. After correction of whole blood
glucose values into plasma values (see Clamp procedure),
the mean plasma glucose level of the normoglycaemic phase
was 5.2 ± 0.8 mmol/l. The duration of the hypoglycaemic
phase ranged from 5 to 660 min; most had a duration of 30,
60 or 120 min. The mean glucose level at hypoglycaemic
nadir was 2.8 ± 0.4 mmol/l, but there was considerable varia-
tion across the studies (ESM Fig. 1). In 173 articles (69.8%),
the glucose nadir was <3.0 mmol/l (mean 2.7 ± 0.2 mmol/l,
range 2.0–2.9), corresponding to level 2 hypoglycaemia
according to the International Hypoglycaemia Study Group
(IHSG) classification [8], whereas the nadir was ≥3.0 mmol/
l (mean 3.2 ± 0.2 mmol/l, range 3.0–4.3) in 75 articles
(30.2%).
Stepped clamp Experiments using stepped clamps varied in
the number of steps (range 1−6). The most frequently used
number of steps after the normoglycaemic phase was four
(36.2%), three (25.4%) or two (19.6%). More than four steps
were used in 10.1% of articles, whereas 4.3% did not provide
information on the number of steps and 4.3% had a
hyperglycaemic step included.
There was a large variation in the duration of the
hypoglycaemic phases for the stepped clamp studies. In the
studies that used four steps, the duration ranged from 20 to
90 min per step, the majority using 45 min (33.3%), 60 min
(25.0%) or 40 min (18.8%). The duration of the steps for
three-step clamps ranged from 20 to 90 min per step, with
60 min (31.6%), 30 min (21.1%) or 50 min (13.2%) most
frequently applied.
In the four-step clamps, the mean targeted plasma glucose
levels for the consecutive steps were 4.2 ± 0.3 mmol/l, 3.6 ±
0.2 mmol/l, 3.0 ± 0.2 mmol/l and 2.5 ± 0.2 mmol/l,
respectively (Fig. 3a). For the three-step clamps, these
numbers averaged 4.1 ± 0.4 mmol/l, 3.4 ± 0.4 mmol/l and
2.8 ± 0.4 mmol/l (Fig. 3b). The mean glucose nadir for the
stepped clamps was 2.6 ± 0.3 mmol/l (range 1.9–3.3), with
2.5 mmol/l (22.4%) or 2.8 mmol/l (16.5%) targetedmost often
(ESM Fig. 2). Eighty-two per cent of the studies had a glucose
nadir <3.0 mmol/l (mean 2.5 ± 0.4 mmol/l, range 1.9–2.9) and
18% a nadir ≥3.0 mmol/l (mean 3.1 ± 0.1 mmol/l, range 3.0–
3.3).
Discussion
The main finding of this study is that there is substantial vari-
ation in the conduction of hyperinsulinaemic–hypoglycaemic
clamps across research groups, particularly in terms of ante-
cedent day preparation, IIRs, number of hypoglycaemic steps,






















































Fig. 3 Hypoglycaemic steps in (a) four-stepped and (b) three-stepped
clamps. Data are shown in a box, representing 25th–75th percentiles,
and whiskers showing 10th and 90th percentiles
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hypoglycaemic nadirs and duration of the clamps. The meth-
odology descriptions frequently lacked important information
in that less than half of the articles provided all the information
needed to evaluate the experiment. Clamps were usually
performed in the morning, in fasting condition, with or with-
out some form of standardisation of meals ingested the
evening before the clamp. Also, most studies included instruc-
tions for people with insulin-treated diabetes to adjust insulin
use to avoid (nocturnal) hypoglycaemia prior to clamping.
Only one of ten studies imposed other lifestyle restrictions
before the clamp, such as refraining from alcohol or caffeine
intake, smoking or engaging in strenuous exercise, which can
affect glucose homeostasis and responses to hypoglycaemia
[9–14], although the duration of these restrictions varied from
12–24 h [15, 16] to 72 h [17, 18]. More than half of the
experiments were done in participants without diabetes and
only around 7% of participants had type 2 diabetes.
There was an almost 50-fold difference between the
highest and lowest IIRs used during the clamps, not including
the doubling of the insulin dose that some studies applied to
reach the lowest glucose target in stepped clamps. In addition,
many studies with participants with type 2 diabetes increased
the IIR at the lowest glucose level to ensure it was maintained
in the face of insulin resistance and a brisk counterregulatory
response. Apart from its effect on glucose requirements,
changing the ambient insulin level may affect outcomes, such
as the response of counterregulatory hormones. The direction
of this change is not known, with some studies observing
lower counterregulatory responses of high-dose vs low-dose
insulin [19] and others finding the exact opposite, albeit all in
healthy men [20, 21]. Another study, performed in partici-
pants with type 1 diabetes, did not find a difference in
counterregulatory hormone responses between high- or low-
dose IIRs [22]. It should be noted that even the lower insulin
doses are often unphysiologically elevated, as this is needed to
achieve hypoglycaemia.
Whether the IIRs are calculated on the basis of body weight
or BSA does not seem to be relevant. Indeed, the CVs of
achieved plasma insulin levels across participants as an esti-
mate of inter-individual insulin variability did not reveal
meaningful differences between the two calculation methods.
It should be noted, however, that only very few studies includ-
ed obese individuals, which is relevant because obesity has a
much greater effect on the calculated insulin dose when this is
based on body weight rather than on BSA. Indeed, for the
abovementioned person (75 kg, BSA 1.94 m2), the calculated
insulin doses for an IIR of 60 mU m−2 min−1 or
1.5 mU kg−1 min−1 are about similar (6.98 vs 6.75 U/h), yet
when this person weighs 125 kg (BSA 2.41 m2), these doses
equal 8.68 and 11.25 U/h, respectively.
An important indicator of the quality of a glucose clamp is
the CV of achieved plasma glucose levels for each glucose
step. The CV reflects the stability of the glucose levels
achieved during the clamp; the lower the CV, the more stable
the clamp. Although there is no formal consensus on how low
the CV of glucose levels should be during a hypoglycaemic
clamp, a CV <5% is generally considered desirable [23].
However, this was achieved in only about a third of the arti-
cles, and it is plausible that CVs are worse in articles that
neither reported nor provided the option to calculate the CV.
Soluble short-acting human insulin was used in the major-
ity of the clamps, although some studies also used porcine
insulin [24]. Since rapid-acting insulin analogues and human
insulin possess the same pharmacodynamic and pharmacoki-
netic qualities when administered directly into the blood-
stream, the choice of insulin is not considered to affect the
outcome of the experiment itself. In the early days of clamp
history, a priming insulin dose was often administered to
quickly achieve target insulin levels. However, due to the very
short t½ of insulin, such a priming dose is probably unneces-
sary for insulin doses below ~2 mU kg−1 min−1
(~80 mU m−2 min−1) [25] and increases the risk that glucose
levels fall too quickly. For higher insulin doses, a priming
dose has been calculated to shorten the time until reaching
steady-state glucose disposal in normoglycaemic glucose
clamps [26].
Data on GIRs were not systematically reported. Ideally,
they should be reported separately for each glycaemic phase.
The GIR during hypoglycaemia is a surrogate marker of the
combined counterregulatory hormone response, reflecting the
inverse of endogenous glucose appearance resulting from
hormonal counterregulation.
Most, but not all, clamps using venous blood sampling
applied some form of hand warming to achieve arterialisation
of venous blood. Because insulin stimulates glucose uptake in
skeletal muscle, peripheral venous samples underestimate, to a
variable degree, the glucose concentrations in the blood supply-
ing tissues, most importantly the brain. Proper hand warming
opens arteriovenous shunts, resulting in arterialisation of
venous blood. Liu et al. found an arteriovenous difference for
high and low IIRs of 0.9 ± 0.1 and 0.4 ± 0.1 mmol/l, respective-
ly [27], whereas the arterial–arterialised venous blood differ-
ence was about 0.1 mmol/l (95% CI −0.2, 0.4) [28]. The heated
hand box method, by which the local temperature is raised in a
controllable way to 55–60°C, is widely used to arterialise
venous blood [28]. However, the method by which blood is
arterialised is less important, as long as the temperature is suffi-
ciently elevated. Indeed, raising the temperature to 40°C with
warm blankets was found to be equally effective as the heated
hand box [29]. It should be acknowledged that although the
arterialisation method is reasonably well validated for glucose,
this may not be the case for other compounds (e.g.
counterregulatory hormones) [30], indicating that it is not possi-
ble to arterialise venous blood completely.
The vast majority of articles reported measurement of
glucose levels in plasma, while the remainder of the articles
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reported these to be measured in whole blood. This is impor-
tant, because, depending on the haematocrit, glucose levels
are approximately 11% lower in whole blood than in plasma
[31]. Indeed, most point-of-care glucose meters use standard
algorithms to convert glucose measured in whole blood to
plasma glucose. Also, the haematocrit may not be stable
during clamps, which introduces bias. There is a high risk of
misinterpretation when data in studies are compared without
considering the source of glucose measurement from either
whole blood or plasma. This is particularly relevant for the
determination of hypoglycaemic thresholds, e.g. for release of
counterregulatory hormones and deterioration of cognitive
function, which inform decisions on the cut-offs used in the
current classification for hypoglycaemia [8].
In 2017, the IHSG proposed glucose levels <3.0 mmol/l
(<54 mg/dl), coined as clinically important hypoglycaemia, to
be reported in clinical studies, so as to enable comparing of the
effectiveness of interventions with hypoglycaemia as an
endpoint [8]. The majority of the clamp studies that we inves-
tigated included a glucose level around this value, but about one
of every four single-step clamps used a glucose nadir that was
substantially higher (up to 4.3 mmol/l). The 3.0 mmol/l thresh-
old level is the result of consensus and analyses are currently
being conducted to refine and solidify the level [32]. For
comparability reasons, it could be argued to always include
such a refined threshold value in future hypoglycaemic glucose
clamps, whether involving one or multiple steps.
There was also substantial variability with respect to the
duration of the hypoglycaemic steps used in both the single-
step and the stepped clamps. Whereas a duration of
hypoglycaemia as short as 5 min (at 2.9 mmol/l) has been
reported to initiate the process of habituation [33], a common
protocol in clamp studies is to take approximately 20 min to
reach that level and another 20 min to revert back from
hypoglycaemia. The CGM definition of hypoglycaemia
requires such an event to last for a minimum of 15 min, with
prolonged hypoglycaemia defined as an episode of at least
120 min [34]. On the other hand, long duration of
hypoglycaemia can be seen as highly unphysiological, affect-
ing both the counterregulatory response [35] and potentially
other outcomes. It seems plausible that the longer the duration
of the hypoglycaemic phase, the more discomfort this may
cause, so that a maximum duration of 30–60 min seems
reasonable.
A total of 11 studies in this systematic review were
performed in children (age range, 6.4–18.0 years), ten of
which included children with type 1 diabetes. The methodol-
ogy of the study protocols in the paediatric population was
very similar to those of adult populations with respect to IIRs,
glucose targets and overall duration. However, since the
number of studies is small, extrapolating our findings in the
adult population to children should be done with caution,
particularly since the younger age group (<12 years) is
underrepresented.
This review has limitations. Due to the large number of
articles, some of which dated back >40 years, we only extract-
ed information from the article itself and chose not to contact
the authors. Also, we focused on type 1 and type 2 diabetes.
Studies involving people with insulinomas [36], pancreatic
transplantation [37], gastric bypass [38] or other conditions
unrelated to diabetes were therefore excluded to minimise
potential further methodological variability. Information
about the use of albumin or the participants’ blood to prevent
insulin from sticking to the infusion sets was very sparse.
Similarly, very few studies provided information about the
addition of potassium to the glucose/insulin infusion to avoid
hypokalaemia and the potential arrhythmia-provoking conse-
quences [39]. However, the lack of such information may
suggest these adverse events to be extremely uncommon.
More than 60% of the articles lacked other important informa-
tion, which may reduce the validity for assessing data and
comparing studies.
In conclusion, there is substantial variation in how
hyperinsulinaemic–hypoglycaemic clamps have been
conducted and reported in the past >40 years. This variation
may potentially impact or raise questions about the validity of
outcomes, and certainly makes it difficult, if not impossible, to
compare results across studies. International consensus to
standardise the design of both single-step and stepped clamps
is therefore urgently needed.
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